A century after researchers from the University of Toronto discovered the hormone as a treatment for diabetes in humans, insulin—and recombinant DNA versions brought to market in the past four decades ...
Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease ...
SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a member of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results